Success Metrics

Active Trials
3(100%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_3
2
67%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Active, not recruiting2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 21 (33.3%)
Phase 32 (66.7%)

Trials by Status

active_not_recruiting267%
recruiting133%

Recent Activity

3 active trials
Showing 3 of 3
recruitingphase_2

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

NCT07116746
active_not_recruitingphase_3

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)

NCT06846515
active_not_recruitingphase_3

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)

NCT06439602

Clinical Trials (3)

Showing 3 of 3 trials
NCT07116746Phase 2

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

Recruiting
NCT06846515Phase 3

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)

Active Not Recruiting
NCT06439602Phase 3

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)

Active Not Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3